Pharmacist-driven Implementation of Fast Identification and Antimicrobial Susceptibility Testing Improves Outcomes for Patients with Gram-negative Bacteremia and Candidemia. Antimicrob Agents Chemother • July 1, 2020
IMPACT OF GLUCOCORTICOID TREATMENT IN SARS-COV-2 INFECTION MORTALITY: A RETROSPECTIVE CONTROLLED COHORT STUDY. Antimicrob Agents Chemother • June 24, 2020
Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus. Antimicrob Agents Chemother • April 25, 2020
A multicenter study of the real-world use of ceftaroline versus vancomycin for acute bacterial skin and skin structure infections. Antimicrob Agents Chemother • August 14, 2019
Clinical and Microbiological Outcomes in Obese Patients Receiving Colistin for Carbapenem-Resistant Gram-negative Bloodstream Infection. Antimicrob Agents Chemother • June 27, 2019
Moxifloxacin in COPD: pharmacokinetics and penetration into bronchial secretions in ward and ICU patients. Antimicrob Agents Chemother • January 16, 2019
Patients at Risk for Aortic Rupture Often Exposed to Fluoroquinolones During Hospitalization. Antimicrob Agents Chemother • November 28, 2018
Efficacy of short-course antibiotic treatments for community-acquired pneumonia in adults: A systematic review and meta-analysis. Antimicrob Agents Chemother • July 11, 2018
Tapering Courses of Oral Vancomycin Induce Persistent Disruption of the Microbiota that Provide Colonization Resistance to Clostridium difficile and Vancomycin-Resistant Enterococci in Mice. Antimicrob Agents Chemother • March 14, 2018
Treatment of Clostridium difficile infection with a small molecule inhibitor of toxin UDP-glucose hydrolysis activity. Antimicrob Agents Chemother • February 28, 2018